Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma

Zong Ren Wang, Jin Huan Wei, Jian Cheng Zhou, Ahmed Haddad, Liang Yun Zhao, Payal Kapur, Kai Jie Wu, Bin Wang, Yan Hong Yu, Bing Liao, Da Lin He, Wei Chen, Vitaly Margulis, Jer Tsong Hsieh, Jun Hang Luo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We have recently reported tumor suppressive role of DAB2IP in RCC development. In this study, We identified one CpG methylation biomarker (DAB2IP CpG1) located UTSS of DAB2IP that was associated with poor overall survival in a cohort of 318 ccRCC patients from the Cancer Genome Atlas (TCGA). We further validated the prognostic accuracy of DAB2IP CpG methylation by pyrosequencing quantitative methylation assay in 224 ccRCC patients from multiple Chinese centers (MCHC set), and 239 patients from University of Texas Southwestern Medical Center at Dallas (UTSW set) by using FFPE samples. DAB2IP CpG1 can predict the overall survival of patients in TCGA, MCHC, and UTSW sets independent of patient age, Fuhrman grade and TNM stage (all p <0.05). DAB2IP CpG1 successfully categorized patients into high-risk and low-risk groups with significant differences of clinical outcome in respective clinical subsets, regardless of age, sex, grade, stage, or race (HR: 1.63-7.83; all p <0.05). The detection of DAB2IP CpG1 methylation was minimally affected by ITH in ccRCC. DAB2IP mRNA expression was regulated by DNA methylation in vitro. DAB2IP CpG1 methylation is a practical and repeatable biomarker for ccRCC, which can provide prognostic value that complements the current staging system.

Original languageEnglish (US)
Pages (from-to)31508-31519
Number of pages12
JournalOncotarget
Volume7
Issue number21
DOIs
StatePublished - May 24 2016

Fingerprint

Renal Cell Carcinoma
Methylation
Atlases
Biomarkers
Genome
Neoplasms
Survival
DNA Methylation
Messenger RNA

Keywords

  • DAB2IP
  • DNA methylation
  • Intratumour heterogeneity
  • Prognosis
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. / Wang, Zong Ren; Wei, Jin Huan; Zhou, Jian Cheng; Haddad, Ahmed; Zhao, Liang Yun; Kapur, Payal; Wu, Kai Jie; Wang, Bin; Yu, Yan Hong; Liao, Bing; He, Da Lin; Chen, Wei; Margulis, Vitaly; Hsieh, Jer Tsong; Luo, Jun Hang.

In: Oncotarget, Vol. 7, No. 21, 24.05.2016, p. 31508-31519.

Research output: Contribution to journalArticle

Wang, ZR, Wei, JH, Zhou, JC, Haddad, A, Zhao, LY, Kapur, P, Wu, KJ, Wang, B, Yu, YH, Liao, B, He, DL, Chen, W, Margulis, V, Hsieh, JT & Luo, JH 2016, 'Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma', Oncotarget, vol. 7, no. 21, pp. 31508-31519. https://doi.org/10.18632/oncotarget.8971
Wang, Zong Ren ; Wei, Jin Huan ; Zhou, Jian Cheng ; Haddad, Ahmed ; Zhao, Liang Yun ; Kapur, Payal ; Wu, Kai Jie ; Wang, Bin ; Yu, Yan Hong ; Liao, Bing ; He, Da Lin ; Chen, Wei ; Margulis, Vitaly ; Hsieh, Jer Tsong ; Luo, Jun Hang. / Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 21. pp. 31508-31519.
@article{612d8f1dfdcd4162a75f4ad7399ab112,
title = "Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma",
abstract = "We have recently reported tumor suppressive role of DAB2IP in RCC development. In this study, We identified one CpG methylation biomarker (DAB2IP CpG1) located UTSS of DAB2IP that was associated with poor overall survival in a cohort of 318 ccRCC patients from the Cancer Genome Atlas (TCGA). We further validated the prognostic accuracy of DAB2IP CpG methylation by pyrosequencing quantitative methylation assay in 224 ccRCC patients from multiple Chinese centers (MCHC set), and 239 patients from University of Texas Southwestern Medical Center at Dallas (UTSW set) by using FFPE samples. DAB2IP CpG1 can predict the overall survival of patients in TCGA, MCHC, and UTSW sets independent of patient age, Fuhrman grade and TNM stage (all p <0.05). DAB2IP CpG1 successfully categorized patients into high-risk and low-risk groups with significant differences of clinical outcome in respective clinical subsets, regardless of age, sex, grade, stage, or race (HR: 1.63-7.83; all p <0.05). The detection of DAB2IP CpG1 methylation was minimally affected by ITH in ccRCC. DAB2IP mRNA expression was regulated by DNA methylation in vitro. DAB2IP CpG1 methylation is a practical and repeatable biomarker for ccRCC, which can provide prognostic value that complements the current staging system.",
keywords = "DAB2IP, DNA methylation, Intratumour heterogeneity, Prognosis, Renal cell carcinoma",
author = "Wang, {Zong Ren} and Wei, {Jin Huan} and Zhou, {Jian Cheng} and Ahmed Haddad and Zhao, {Liang Yun} and Payal Kapur and Wu, {Kai Jie} and Bin Wang and Yu, {Yan Hong} and Bing Liao and He, {Da Lin} and Wei Chen and Vitaly Margulis and Hsieh, {Jer Tsong} and Luo, {Jun Hang}",
year = "2016",
month = "5",
day = "24",
doi = "10.18632/oncotarget.8971",
language = "English (US)",
volume = "7",
pages = "31508--31519",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "21",

}

TY - JOUR

T1 - Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma

AU - Wang, Zong Ren

AU - Wei, Jin Huan

AU - Zhou, Jian Cheng

AU - Haddad, Ahmed

AU - Zhao, Liang Yun

AU - Kapur, Payal

AU - Wu, Kai Jie

AU - Wang, Bin

AU - Yu, Yan Hong

AU - Liao, Bing

AU - He, Da Lin

AU - Chen, Wei

AU - Margulis, Vitaly

AU - Hsieh, Jer Tsong

AU - Luo, Jun Hang

PY - 2016/5/24

Y1 - 2016/5/24

N2 - We have recently reported tumor suppressive role of DAB2IP in RCC development. In this study, We identified one CpG methylation biomarker (DAB2IP CpG1) located UTSS of DAB2IP that was associated with poor overall survival in a cohort of 318 ccRCC patients from the Cancer Genome Atlas (TCGA). We further validated the prognostic accuracy of DAB2IP CpG methylation by pyrosequencing quantitative methylation assay in 224 ccRCC patients from multiple Chinese centers (MCHC set), and 239 patients from University of Texas Southwestern Medical Center at Dallas (UTSW set) by using FFPE samples. DAB2IP CpG1 can predict the overall survival of patients in TCGA, MCHC, and UTSW sets independent of patient age, Fuhrman grade and TNM stage (all p <0.05). DAB2IP CpG1 successfully categorized patients into high-risk and low-risk groups with significant differences of clinical outcome in respective clinical subsets, regardless of age, sex, grade, stage, or race (HR: 1.63-7.83; all p <0.05). The detection of DAB2IP CpG1 methylation was minimally affected by ITH in ccRCC. DAB2IP mRNA expression was regulated by DNA methylation in vitro. DAB2IP CpG1 methylation is a practical and repeatable biomarker for ccRCC, which can provide prognostic value that complements the current staging system.

AB - We have recently reported tumor suppressive role of DAB2IP in RCC development. In this study, We identified one CpG methylation biomarker (DAB2IP CpG1) located UTSS of DAB2IP that was associated with poor overall survival in a cohort of 318 ccRCC patients from the Cancer Genome Atlas (TCGA). We further validated the prognostic accuracy of DAB2IP CpG methylation by pyrosequencing quantitative methylation assay in 224 ccRCC patients from multiple Chinese centers (MCHC set), and 239 patients from University of Texas Southwestern Medical Center at Dallas (UTSW set) by using FFPE samples. DAB2IP CpG1 can predict the overall survival of patients in TCGA, MCHC, and UTSW sets independent of patient age, Fuhrman grade and TNM stage (all p <0.05). DAB2IP CpG1 successfully categorized patients into high-risk and low-risk groups with significant differences of clinical outcome in respective clinical subsets, regardless of age, sex, grade, stage, or race (HR: 1.63-7.83; all p <0.05). The detection of DAB2IP CpG1 methylation was minimally affected by ITH in ccRCC. DAB2IP mRNA expression was regulated by DNA methylation in vitro. DAB2IP CpG1 methylation is a practical and repeatable biomarker for ccRCC, which can provide prognostic value that complements the current staging system.

KW - DAB2IP

KW - DNA methylation

KW - Intratumour heterogeneity

KW - Prognosis

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84971570800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971570800&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8971

DO - 10.18632/oncotarget.8971

M3 - Article

VL - 7

SP - 31508

EP - 31519

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 21

ER -